Key result
Genetic DCM accounts for ~30% of cases and relies on standard HF therapies.
Why the study?
Genetic causes are identifiable in 25% to 30% of patients with dilated cardiomyopathy, necessitating a review of pathophysiology, associated genes, and therapies.
This review summarizes the pathophysiology, genetics, and therapeutic options for genetic dilated cardiomyopathy, which accounts for 25% to 30% of DCM cases.
Standard HF therapies and arrhythmia stratification guide genetic DCM care; leaves open targeted gene therapy development.
Dilated cardiomyopathy (DCM) is a leading cause of nonischemic heart failure. Genetic causes are identifiable in 25% to 30% of patients. This review describes the pathophysiology underlying genetic DCM, the genes most strongly associated with DCM, and both standard and novel therapies for treating genetic DCM.
No takes yet. Share an insight, caveat, or question.
Boslough et al. (2026) conducted a review in Genetic Dilated Cardiomyopathy. Genetic dilated cardiomyopathy accounts for 25% to 35% of cases and is primarily managed with standard heart failure therapies and risk stratification for arrhythmias, as targeted gene therapies are not yet in clinical practice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: